KR101687644B1 - Ｈｉｖ 감염 치료를 위한 ｎ-히드록시벤즈아미드의 유도체 - Google Patents

Ｈｉｖ 감염 치료를 위한 ｎ-히드록시벤즈아미드의 유도체 Download PDF

Info

Publication number
KR101687644B1
KR101687644B1 KR1020127007623A KR20127007623A KR101687644B1 KR 101687644 B1 KR101687644 B1 KR 101687644B1 KR 1020127007623 A KR1020127007623 A KR 1020127007623A KR 20127007623 A KR20127007623 A KR 20127007623A KR 101687644 B1 KR101687644 B1 KR 101687644B1
Authority
KR
South Korea
Prior art keywords
inhibitor
pharmaceutical composition
composition according
hiv
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127007623A
Other languages
English (en)
Korean (ko)
Other versions
KR20120083356A (ko
Inventor
찰스 디나렐로
지안루카 포사티
파올로 마스카그니
Original Assignee
이탈파마코 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이탈파마코 에스.피.에이. filed Critical 이탈파마코 에스.피.에이.
Publication of KR20120083356A publication Critical patent/KR20120083356A/ko
Application granted granted Critical
Publication of KR101687644B1 publication Critical patent/KR101687644B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127007623A 2009-10-23 2010-09-14 Ｈｉｖ 감염 치료를 위한 ｎ-히드록시벤즈아미드의 유도체 Expired - Fee Related KR101687644B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A001837A IT1396915B1 (it) 2009-10-23 2009-10-23 Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
ITMI2009A001837 2009-10-23
PCT/IB2010/054139 WO2011048514A1 (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Publications (2)

Publication Number Publication Date
KR20120083356A KR20120083356A (ko) 2012-07-25
KR101687644B1 true KR101687644B1 (ko) 2016-12-19

Family

ID=42153811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007623A Expired - Fee Related KR101687644B1 (ko) 2009-10-23 2010-09-14 Ｈｉｖ 감염 치료를 위한 ｎ-히드록시벤즈아미드의 유도체

Country Status (10)

Country Link
US (1) US8637702B2 (enExample)
EP (1) EP2490682A1 (enExample)
JP (1) JP5746196B2 (enExample)
KR (1) KR101687644B1 (enExample)
CN (1) CN102548551A (enExample)
BR (1) BR112012008780A2 (enExample)
CA (1) CA2773210C (enExample)
IN (1) IN2012DN03387A (enExample)
IT (1) IT1396915B1 (enExample)
WO (1) WO2011048514A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345905B2 (en) * 2011-11-29 2016-05-24 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents
MX349767B (es) 2012-02-03 2017-08-11 Italfarmaco Spa Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
WO2022088047A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Itf2357在制备预防和治疗冠状病毒的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003068A2 (en) 2004-07-05 2006-01-12 Italfarmaco Spa Alpha-amino acid derivatives with antiinflammatory activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
AU2005223659A1 (en) * 2004-03-18 2005-09-29 Georgetown University Benzamide and benzoate anti-HIV compounds
WO2008097654A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Methods of using saha for treating hiv infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003068A2 (en) 2004-07-05 2006-01-12 Italfarmaco Spa Alpha-amino acid derivatives with antiinflammatory activity

Also Published As

Publication number Publication date
ITMI20091837A1 (it) 2011-04-23
CN102548551A (zh) 2012-07-04
JP5746196B2 (ja) 2015-07-08
EP2490682A1 (en) 2012-08-29
IN2012DN03387A (enExample) 2015-10-23
CA2773210C (en) 2017-01-03
IT1396915B1 (it) 2012-12-20
US20120203014A1 (en) 2012-08-09
KR20120083356A (ko) 2012-07-25
BR112012008780A2 (pt) 2020-12-01
JP2013508349A (ja) 2013-03-07
CA2773210A1 (en) 2011-04-28
WO2011048514A1 (en) 2011-04-28
US8637702B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
US8247613B2 (en) Methods and compositions for the synergistic activation of latent HIV
US20240390375A1 (en) Methods and compositions for treating viral or virally-induced conditions
KR101687644B1 (ko) Ｈｉｖ 감염 치료를 위한 ｎ-히드록시벤즈아미드의 유도체
Rasmussen et al. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials
US20150133434A1 (en) Compositions and Methods for Reactivating Latent Immunodeficiency Virus
US20030235588A1 (en) Method of treating TRX mediated diseases
JP2016519166A (ja) Ｈｉｖ感染症を処置するための方法および組成物
US20100324034A1 (en) Methods of Using SAHA for Treating HIV Infection
US10184933B2 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof
US20230087766A1 (en) Methods of reactivating latent human immunodeficiency virus and related compositions
Lim et al. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor
EP1627635B1 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
CA2637590C (en) Treatment of inflammatory disorders with triazole compounds
US9956260B1 (en) Treatment of HIV-1 infection and AIDS
WO2021113632A1 (en) A combination therapy approach to eliminate hiv infections
EA027810B1 (ru) Гетероциклические карбоксамиды для лечения вирусных заболеваний
KR20110096028A (ko) 잠복성 hiv 감염 세포에서 hiv-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제
US10633363B2 (en) EPAC1 activators as HIV latency reversal agents (LRA)
WO2021090194A1 (en) Treatment of malaria using histone deacetylase (hdac) inhibitors
KR20230167064A (ko) 염증 치료 방법
US11554123B2 (en) Compositions and methods for reactivating latent HIV-1 infections
WO2025183089A1 (ja) 潜伏感染しているｈｉｖを再活性化するための組成物
US11701374B1 (en) 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression
AU2005227400A1 (en) Method of Treating TRX Mediated Diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221214

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221214